This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer in clinical practice. Data will be collected for each patient for 18 months from initiation of Avastin therapy.

Inclusion Criteria:

• Adult patients, >/= 18 years of age
• Inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)
• Treating physician's decision to initiate first-line Avastin treatment

Exclusion Criteria:

• Participation in a clinical trial evaluating anti-cancer therapies

Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer